Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김현영 | - |
dc.date.accessioned | 2017-02-27T02:08:58Z | - |
dc.date.available | 2017-02-27T02:08:58Z | - |
dc.date.issued | 2015-06 | - |
dc.identifier.citation | STEM CELLS TRANSLATIONAL MEDICINE, v. 4, NO 6, Page. 590-597 | en_US |
dc.identifier.issn | 2157-6564 | - |
dc.identifier.issn | 2157-6580 | - |
dc.identifier.uri | http://onlinelibrary.wiley.com/doi/10.5966/sctm.2014-0212/full | - |
dc.identifier.uri | http://hdl.handle.net/20.500.11754/25687 | - |
dc.description.abstract | Stem cell therapy is an emerging alternative therapeutic or disease-Modifying strategy for amyotrophic lateral sclerosis (ALS). The aim of this open-label phase I clinical trial was to evaluate the safety of two repeated intrathecal injections of autologous. bone marrow (BM)-derived mesenchymal stromal cells (MSCs) in ALS patients. Eight patients with definite or probable ALS were enrolled. After a 3-month lead-in period, autologous MSCs were isolated two times from the BM at an interval of 26 days and were then expanded in vitro for 28 days and suspended in autologous cerebrospinal fluid. Of the 8 patients, 7 received 2 intrathecal injections of a utologous MSCs (1 x 10(6) cells per kg) 26 days apart. Clinical or laboratory measurements were recorded to evaluate the safety 12 months after the first MSC injection. The ALS Functional Rating Scale-Revised (ALSFRS-R), the Appel ALS score, and forced vital capacity were used to evaluate the patients' disease status. One patient died before treatment and was withdrawn from the study. With the exception of that patient, no-serious adverse events were observed during the 12-month follow-up period. Most of the adverse events were self-limited or subsided after supportive treatment within 4 days. Decline in the ALSFRS-R score was not accelerated during the 6-month follow-up period. Two repeated intrathecal injections of autologous MSCs were safe and feasible throughout the duration of the 12-month follow-up period. | en_US |
dc.description.sponsorship | This study was supported by grants from the Korea Healthcare Technology R&D Project of the Ministry for Health & Welfare Affairs, Republic of Korea (HI10C1673). This study would not have been possible without the participation of the patients and their-families. We also thank the ALS nurse specialists at the Hanyang ALS Clinic (Ji Won An, Juyeon Oh, Hanna Lim, and Bo Kyeong Hwang) for their helpful support. K.-W.O. and S.H.K. had full access to all the data in this study and take responsibility for the integrity of the data and the accuracy of the data analysis. | en_US |
dc.language.iso | en | en_US |
dc.publisher | ALPHAMED PRESS | en_US |
dc.subject | Amyotrophic lateral sclerosis | en_US |
dc.subject | Clinical trials | en_US |
dc.subject | Mesenchymal stromal cells | en_US |
dc.subject | Intrathecal | en_US |
dc.title | Phase I Trial of Repeated Intrathecal Autologous Bone Marrow-Derived Mesenchymal Stromal Cells in Amyotrophic Lateral Sclerosis | en_US |
dc.type | Article | en_US |
dc.relation.no | 6 | - |
dc.relation.volume | 4 | - |
dc.identifier.doi | 10.5966/sctm.2014-0212 | - |
dc.relation.page | 590-597 | - |
dc.relation.journal | STEM CELLS TRANSLATIONAL MEDICINE | - |
dc.contributor.googleauthor | Oh, Ki-Wook | - |
dc.contributor.googleauthor | Moon, Chanil | - |
dc.contributor.googleauthor | Kim, Hyun Young | - |
dc.contributor.googleauthor | Oh, Sung-Il | - |
dc.contributor.googleauthor | Park, Jinseok | - |
dc.contributor.googleauthor | Lee, Jun Ho | - |
dc.contributor.googleauthor | Chang, In Young | - |
dc.contributor.googleauthor | Kim, Kyung Suk | - |
dc.contributor.googleauthor | Kim, Seung Hyun | - |
dc.relation.code | 2015006228 | - |
dc.sector.campus | S | - |
dc.sector.daehak | COLLEGE OF MEDICINE[S] | - |
dc.sector.department | DEPARTMENT OF MEDICINE | - |
dc.identifier.pid | hyoungkim1 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.